Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles
Advanced Healthcare Materials · 2026-11 · 15 (41)
DOI: 10.1002/adhm.202504351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 16.07.2026. Verfasst von Chiranth K Nagaraj und 23 weiteren Autor:innen. Beteiligte Einrichtung: William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Erythrocytes, Lipids, Microfluidics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCATS NIH HHS, National Cancer Institute, Bethesda.
Abstract (Originalsprache)
A central challenge in nanomedicine is the scalable and precise engineering of nanocarriers that are simultaneously tunable, immune‐compatible, and capable of encapsulating diverse bioactive cargos. Extracellular vesicles (EVs), including native red blood cell‐derived EVs (RBCEVs), offer biocompatibility but remain limited by heterogeneous composition, low yield, poor scalability, and limited control in cargo loading. Here, we introduce a bottom‐up strategy for developing engineered red blood cell extracellular vesicles (eRBCEVs) through microfluidic diffusional mixing of purified RBC lipids and components. Parametric optimization through multi‐physics simulation enabled predictive control over flow rates, lipid concentration, and channel geometry. eRBCEVs exhibited comparable encapsulation efficiency across molecular cargos of distinct sizes and properties, including oligonucleotides, gold nanoparticles, hemoglobin, erythrocruorin (∼3.6 MDa), and full adeno‐associated virus (AAV ∼25 nm) particles, validated through cryo‐EM, chemical mapping, and high‐resolution TIRFM. Surface conjugation with CD47 peptide was established for comparison with RBCEVs; the bio‐conjugations with α‐PD‐L1 antibodies yielded functionalized vesicles with uptake in PD‐L1‐positive human tumor organoids. In vivo biodistribution and pharmacokinetic analysis in mice demonstrated sustained circulation and tissue distribution in the liver, spleen, and lungs. Neutrophil activation and macrophage uptake assays confirmed minimal immunogenicity compared to conventional particles and free‐protein controls. Collectively, our platform enables the scalable synthesis of customizable eRBCEVs that preserve RBC lipid features, support cargo flexibility, and potential for scale‐up. This work establishes eRBCEVs as a next‐generation therapeutic platform for programmable, patient‐specific delivery in gene therapy, immunomodulation, and translational nanomedicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
- Diabetes and Metabolism Research Center, Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
- Department of Human Sciences, Human Nutrition Program, The Ohio State University, Columbus, Ohio, USA.
- Department of Pediatrics, Center for Clinical and Translational Research, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio, USA.
- Jerry R. Mendell Center for Gene Therapy, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
ORCID-Profile: Chiranth K Nagaraj, Xilal Y Rima, Kim T Nguyen, Dharti Shantaram, Anastasiia Amari, Nicholas R Merriam, Willa A Hsueh, Eduardo Reátegui
Förderung
- NIH HHS
- NCATS NIH HHS
- National Cancer Institute, Bethesda
- NHLBI NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Nagaraj, C. K., Rima, X. Y., Nguyen, K. T., Culkins, C., Boateng, N., Doon-Ralls, J., Bresolin, A., Huang, X., Li, H., Amid, V., Singh, A. P., Shantaram, D., Amari, A., Hade, M. D., Merriam, N. R., Schultz, Z. D., Harper, S. Q., Saad, N. Y., Magaña, S. M., …, & Reátegui, E. (2026). Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles. Advanced Healthcare Materials, 15(41). https://doi.org/10.1002/adhm.202504351
Vancouver
Nagaraj CK, Rima XY, Nguyen KT, Culkins C, Boateng N, Doon-Ralls J, et al. Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles. Advanced Healthcare Materials. 2026;15(41). doi:10.1002/adhm.202504351
BibTeX
@article{Nagaraj2026,
author = {Nagaraj, Chiranth K and Rima, Xilal Y and Nguyen, Kim T and Culkins, Courtney and Boateng, Nana and Doon-Ralls, Jacob and Bresolin, Alejandro and Huang, Xin and Li, Hong and Amid, Vahedi and Singh, Ajeet Pal and Shantaram, Dharti and Amari, Anastasiia and Hade, Mangesh D and Merriam, Nicholas R and Schultz, Zachary D and Harper, Scott Q and Saad, Nizar Y and Magaña, Setty M and Hsueh, Willa A and Kopec, Rachel E and Kimmel, Blaise R and Palmer, Andre F and Reátegui, Eduardo},
title = {Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {41},
doi = {10.1002/adhm.202504351}
}
EUVIMED